Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

Epacadostat is a potent and highly selective inhibitor of indoleamine 2,3‐dioxygenase 1 (IDO1). Here we report results from the open‐label, dose‐escalation, Phase 1b ECHO‐110 study evaluating epacadostat plus atezolizumab in patients with previously treated Stage IIIB/IV nonsmall cell lung cancer (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellmann, Matthew D., Gettinger, Scott, Chow, Laura Q. M., Gordon, Michael, Awad, Mark M., Cha, Edward, Gong, Xiaohua, Zhou, Gongfu, Walker, Chris, Leopold, Lance, Heist, Rebecca S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496129/
https://www.ncbi.nlm.nih.gov/pubmed/32141617
http://dx.doi.org/10.1002/ijc.32951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496129/
https://www.ncbi.nlm.nih.gov/pubmed/32141617
http://dx.doi.org/10.1002/ijc.32951

Ejemplares similares